Endocrine Abstracts

Aim: To evaluate influence of cabergoline on LAO and BAS processes in treatment of patients with NFPA.

Materials and methods: We included 64 patients with NFPA in the study. Mean age was 43.6±3.84 years (range 30–55 years). Of 64 patients 26 (40.6%) were men and 38 (59.4%) were women. Duration of the disease from diagnosis based on MRI constituted 1–15 years. Severity criteria used in the evaluation were LH, FSH and prolactin (PRL) growth as well as progression of neurological and vision problems.

Results and discussion: Before treatment FSH, LH and PRL levels in patients with NFPA were 18.3, 20.9, and 50.4% (P<0.05, P<0.01, P<0.001) higher then in controls (10 healthy men and 10 healthy women). The same time there was noticed different concentration of CL and MDA which defined depending on the duration of the disease and tumor size. We revealed different variants of BAS enzymes activity such as SOD, CT, GP and GR. In patients with NFPA with the duration of the disease from 8 to 15 years LAO high intensity associated with inhibition of BAS enzymes. 0.25 cabergoline use during 3 months associated with inhibition of FSH, LH, 15.8% (P<0.05) decrease in PRL levels.

Conclusion: Cabergoline increases treatment effect in patients with NFPA by decreasing pituitary hormones levels such as FSH, LH and PRL. However, it practically does not have influence on BAS enzymes activity such as SOD, CT, GP and GR and this approves the add of antioxidative therapy to main treatment.